Literature DB >> 15023490

Well-being and life satisfaction in generalized anxiety disorder: comparison to major depressive disorder in a community sample.

Murray B Stein1, Richard G Heimberg.   

Abstract

BACKGROUND: In most settings, generalized anxiety disorder (GAD) is highly comorbid with major depressive disorder (MDD). This raises uncertainty about the clinical relevance of GAD as a distinct diagnostic entity. The demonstration of functional impairment attached to GAD, independent of that attributable to MDD, would support the importance of GAD as a separate diagnostic category.
METHODS: The Ontario Health Survey Mental Health Supplement, a survey of more than 8000 residents aged 15-64 of the Canadian province of Ontario, used the University of Michigan Composite International Interview Schedule (also used in the US National Comorbidity Survey) to assign DSM-III-R diagnoses. Several indicators of disability and quality of life were included. Our analytic strategy was to compare these indices in persons with and without GAD, stratified by MDD comorbidity, and adjusting for the effects of relevant sociodemographic factors (e.g., social class, age, gender) and dysthymia. Odds ratios (ORs) are reported; SUDAAN was used to adjust for the sampling framework.
RESULTS: GAD was highly comorbid with MDD on both a lifetime and past-year basis. Both past-year and lifetime MDD and GAD were associated with an increased likelihood of low overall perceived well-being. Both lifetime MDD and GAD were associated with dissatisfaction in one's main activity and with family relationships. LIMITATIONS: Other comorbid Axis I or II conditions might be confounders with impairment; a lower rate of GAD than in some prior surveys bears consideration.
CONCLUSIONS: These observations confirm that GAD is associated with an increased likelihood of poor global well-being and life satisfaction, beyond that associated with MDD. Given the chronicity of GAD relative to the more often episodic course of MDD, the long-term functional benefits of treating GAD may be substantial.

Entities:  

Mesh:

Year:  2004        PMID: 15023490     DOI: 10.1016/S0165-0327(02)00457-3

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  23 in total

1.  Human and economic burden of GAD, subthreshold GAD, and worry in a primary care sample.

Authors:  Sarah J Kertz; Janet Woodruff-Borden
Journal:  J Clin Psychol Med Settings       Date:  2011-09

2.  Impairment and functioning in a sample of primary care patients with generalized anxiety disorder: results from the primary care anxiety project.

Authors:  Risa B Weisberg; Courtney Beard; Maria E Pagano; Kristin M Maki; Larry Culpepper; Martin B Keller
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

3.  The Relationship of Anxiety and Depression to Subjective Well-Being in a Mainland Chinese Sample.

Authors:  Christopher Malone; Amy Wachholtz
Journal:  J Relig Health       Date:  2018-02

Review 4.  Non-pharmacological therapies for inflammatory bowel disease: Recommendations for self-care and physician guidance.

Authors:  Whitney Duff; Natasha Haskey; Gillian Potter; Jane Alcorn; Paulette Hunter; Sharyle Fowler
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

5.  Health-related quality of life across the anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions (NESARC).

Authors:  Jonathan S Comer; Carlos Blanco; Deborah S Hasin; Shang-Min Liu; Bridget F Grant; J Blake Turner; Mark Olfson
Journal:  J Clin Psychiatry       Date:  2010-08-24       Impact factor: 4.384

6.  AN OPEN TRIAL OF EMOTION REGULATION THERAPY FOR GENERALIZED ANXIETY DISORDER AND COOCCURRING DEPRESSION.

Authors:  Douglas S Mennin; David M Fresco; Michael Ritter; Richard G Heimberg
Journal:  Depress Anxiety       Date:  2015-05-06       Impact factor: 6.505

7.  Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care.

Authors:  J M Joesch; C D Sherbourne; G Sullivan; M B Stein; M G Craske; P Roy-Byrne
Journal:  Psychol Med       Date:  2011-12-13       Impact factor: 7.723

8.  A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder.

Authors:  Paul J Whalen; Tom Johnstone; Leah H Somerville; Jack B Nitschke; Sara Polis; Andrew L Alexander; Richard J Davidson; Ned H Kalin
Journal:  Biol Psychiatry       Date:  2007-10-26       Impact factor: 13.382

9.  Is generalized anxiety disorder an anxiety or mood disorder? Considering multiple factors as we ponder the fate of GAD.

Authors:  Douglas S Mennin; Richard G Heimberg; David M Fresco; Michael R Ritter
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

10.  Screening for generalized anxiety disorder symptoms in the wake of terrorist attacks: a study in primary care.

Authors:  Bita Ghafoori; Yuval Neria; Marc J Gameroff; Mark Olfson; Rafael Lantigua; Steven Shea; Myrna M Weissman
Journal:  J Trauma Stress       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.